Astrazeneca Plc Stock Retained Earnings
| AZN Stock | SEK 1,454 4.50 0.31% |
AstraZeneca PLC fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
AstraZeneca |
AstraZeneca PLC Company Retained Earnings Analysis
AstraZeneca PLC's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current AstraZeneca PLC Retained Earnings | 8.07 B |
Most of AstraZeneca PLC's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, AstraZeneca PLC has a Retained Earnings of 8.07 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The retained earnings for all Sweden stocks is 13.45% higher than that of the company.
Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
AstraZeneca Fundamentals
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 2.49 T | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 46.67 % | |||
| Price To Earning | 437.97 X | |||
| Price To Book | 6.15 X | |||
| Price To Sales | 49.17 X | |||
| Revenue | 44.35 B | |||
| Gross Profit | 35.73 B | |||
| EBITDA | 9.33 B | |||
| Net Income | 3.29 B | |||
| Cash And Equivalents | 4.89 B | |||
| Cash Per Share | 3.15 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 0.87 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 23.91 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 22.08 X | |||
| Price To Earnings To Growth | 1.36 X | |||
| Target Price | 1636.64 | |||
| Number Of Employees | 37 | |||
| Beta | 0.19 | |||
| Market Capitalization | 2.26 T | |||
| Total Asset | 96.48 B | |||
| Retained Earnings | 8.07 B | |||
| Working Capital | (3.16 B) | |||
| Current Asset | 12.77 B | |||
| Current Liabilities | 15.93 B | |||
| Z Score | 58.8 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 3.03 % | |||
| Net Asset | 96.48 B | |||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.